Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006 Cheng, 2008, Neoplasms of the urinary bladder, 259 Epstein, 1998, The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee, Am J Surg Pathol, 22, 1435, 10.1097/00000478-199812000-00001 Eble, 2004 Lopez-Beltran, 2002, Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation, Virchows Arch, 440, 3, 10.1007/s00428-001-0577-6 Cheng, 1999, Survival of patients with carcinoma in situ of the urinary bladder, Cancer, 85, 2469, 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U McKenney, 2001, Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion, Am J Surg Pathol, 25, 356, 10.1097/00000478-200103000-00010 Montironi, 2008, Morphological classification and definition of the benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder, Histopathology, 53, 621, 10.1111/j.1365-2559.2008.03025.x Emerson, 2005, Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review, Anal Quant Cytol Histol, 27, 301 Desai, 2000, Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia, Mod Pathol, 13, 1315, 10.1038/modpathol.3880241 Requena, 2007, Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review, Anal Quant Cytol Histol, 29, 380 Brunner, 2008, Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system, Anal Quant Cytol Histol, 30, 297 McKenney, 2001, Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens, Am J Surg Pathol, 25, 1074, 10.1097/00000478-200108000-00013 Hartmann, 1999, Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma, Am J Pathol, 154, 721, 10.1016/S0002-9440(10)65318-7 Obermann, 2003, Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses, J Pathol, 199, 50, 10.1002/path.1259 van Oers, 2006, Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder, Int J Cancer, 119, 1212, 10.1002/ijc.21958 Majewski, 2008, Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy, Lab Invest, 88, 694, 10.1038/labinvest.2008.27 Cheng, 2008, Overdiagnosis of bladder carcinoma, Anal Quant Cytol Histol, 30, 261 Sarma, 1981, Genesis of papillary tumours: histological and microangiographic study, Br J Urol, 53, 228, 10.1111/j.1464-410X.1981.tb06094.x Taylor, 1996, Papillary urothelial hyperplasia. A precursor to papillary neoplasms, Am J Surg Pathol, 20, 1481, 10.1097/00000478-199612000-00007 Swierczynski, 2002, Prognostic significance of atypical papillary urothelial hyperplasia, Hum Pathol, 33, 512, 10.1053/hupa.2002.124031 Cheng, 2000, Flat intraepithelial lesions of the urinary bladder, Cancer, 88, 625, 10.1002/(SICI)1097-0142(20000201)88:3<625::AID-CNCR20>3.0.CO;2-A Epstein, 1998, The bladder consensus conference committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder, Am J Surg Pathol, 22, 1435, 10.1097/00000478-199812000-00001 Lopez-Beltran, 2002, Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer, J Clin Pathol, 55, 641, 10.1136/jcp.55.9.641 Kunju, 2005, Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia, Pathol Int, 55, 248, 10.1111/j.1440-1827.2005.01821.x Montironi, 2009, 2004 World Health Organization classification of the noninvasive urothelial neoplasms: inherent problems and clinical reflections, Eur Urol, 8, 453, 10.1016/j.eursup.2008.12.004 Jones, 2006, Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts, J Urol, 175, 1995, 10.1016/S0022-5347(06)00267-9 Maclennan, 2007, Histologic grading of noninvasive papillary urothelial neoplasms, Eur Urol, 51, 889, 10.1016/j.eururo.2006.10.037 Grignon, 2009, The current classification of urothelial neoplasms, Mod Pathol, 22, S60, 10.1038/modpathol.2008.235 Cheng, 2009, Staging and reporting of urothelial carcinoma of the urinary bladder, Mod Pathol, 22, S70, 10.1038/modpathol.2009.1 Cheng, 1999, Natural history of urothelial dysplasia of the bladder, Am J Surg Pathol, 23, 443, 10.1097/00000478-199904000-00009 Chandramouly, 2007, The control of tissue architecture over nuclear organization is crucial for epithelial cell fate, J Cell Sci, 120, 1596, 10.1242/jcs.03439 Shirai, 1987, Epithelail lesions of the urinary bladder in 313 autopsy cases, Jpn J Cancer Res, 78, 1073 Zuk, 1988, Clinicopathological importance of primary dsyplasia of bladder, J Clin Pathol, 41, 1277, 10.1136/jcp.41.12.1277 Baithun, 1988, Primary dysplasia of bladder, Lancet, 1, 483, 10.1016/S0140-6736(88)91287-1 Harnden, 1996, Cytokeratin 20 as an objective marker of urothelial dysplasia, Br J Urol, 78, 870, 10.1046/j.1464-410X.1996.23511.x Spruck, 1994, Two molecular pathways to transitional cell carcinoma of the bladder, Cancer Res, 54, 784 Wu, 2005, Urothelial tumorigenesis: a tale of divergent pathways, Nat Rev Cancer, 5, 713, 10.1038/nrc1697 Baithun, 2001, Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications, Virchows Arch, 438, 289, 10.1007/s004280000289 Baud, 1998, Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion, Int J Cancer, 77, 821, 10.1002/(SICI)1097-0215(19980911)77:6<821::AID-IJC3>3.0.CO;2-W Hart, 2000, Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4, Oncogene, 19, 3309, 10.1038/sj.onc.1203650 Jebar, 2005, FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma, Oncogene, 24, 5218, 10.1038/sj.onc.1208705 Chern, 1996, Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins, J Urol, 156, 1846, 10.1016/S0022-5347(01)65550-2 Fadl-Elmula, 1999, Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding, Br J Cancer, 81, 6, 10.1038/sj.bjc.6690643 Habuchi, 1993, Metachronous multifocal development of urothelial cancers by intraluminal seeding, Lancet, 342, 1087, 10.1016/0140-6736(93)92066-3 Hafner, 2002, Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies, Int J Cancer, 101, 1, 10.1002/ijc.10544 Yoshimura, 1995, p53 gene mutation in recurrent superficial bladder cancer, J Urol, 153, 1711, 10.1016/S0022-5347(01)67510-4 Hafner, 2001, Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract, Oncogene, 20, 4910, 10.1038/sj.onc.1204671 Jones, 2005, Molecular evidence supporting field effect in urothelial carcinogenesis, Clin Cancer Res, 11, 6512, 10.1158/1078-0432.CCR-05-0891 Hartmann, 2000, Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis, Lab Invest, 80, 709, 10.1038/labinvest.3780074 Hartmann, 2002, Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder, Cancer Res, 62, 809 Steidl, 2002, Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium, J Pathol, 198, 115, 10.1002/path.1175 Lee, 2007, Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia, Proc Natl Acad Sci USA, 104, 13732, 10.1073/pnas.0701771104 Tuziak, 2005, High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis, Lab Invest, 85, 689, 10.1038/labinvest.3700270 Lopez-Beltran, 2008, Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium, J Pathol, 215, 263, 10.1002/path.2353